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We present a successful treatment, with tigecycline mono-
therapy, of acute prostatitis caused by multidrug-resistant 
Escherichia coli harboring an NDM-1 carbapemenase along 
with a CMY-2 cephalosporinase and a TEM ESBL.
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CASE
A 79-year-old patient with known bladder neck sclerosis and 
subsequent chronic polyuria and nocturia presented to the 
Department of Urology at Bern University Hospital in March 
2018 with progressive worsening of symptoms over the pre-
ceding 2 weeks and new-onset premicturition pain without 
fever. The history was notable for a prostate adenoma treated 
with transurethral resection of the prostate in 2017 and for 
chronic renal insufficiency (CKD IIIb) since 2015.
Clinical examination revealed marked prostatic tender-
ness. Urine, obtained after prostate massage at admission, 
was nitrite positive, and >40 leucocytes/hpf C-reactive pro-
tein and white blood cell count were normal. Culture of 
urine yielded Escherichia coli at 104 CFU/mL, resistant to 
β-lactam/β-lactamase inhibitor combinations, cephalosporins, 
aminoglycosides, classical tetracyclines, antifolates, fosfomycin, 
and quinolones (Table  1). Microarray analysis (Check-MDR 
CT103XL, CheckPoints, Wageningen, the Netherlands) de-
tected genes for an NDM-1 carbapenemase, CMY-2-acquired 
AmpC, and a TEM 164H  extended-spectrum β-lactamase 
(ESBL).
A diagnosis of acute prostatitis was established. Due to its 
multidrug resistance (MDR) and the lack of reasonable alter-
natives (discussed below), tigecycline therapy was started with 
a loading dose of 100 mg, followed by 50 mg twice daily, and 
continued for 4 weeks. Full relief from the premicturition pain 
and improvement of nocturia and polyuria were apparent at day 
8 of treatment. Follow-up cultures up to 7 months post- treat-
ment did not detect regrowth of the MDR E.  coli. Urinalysis 
after prostate massage, 4  months post-treatment, revealed no 
persistent pyuria; this had disappeared at treatment day 6.
DISCUSSION
This case complements 3 previous reports of prostatitis treated 
with tigecycline [1]; all support the drug’s effectiveness as 
monotherapy for prostatitis with MDR E. coli.
For the present case, the choice of this regimen reflected several 
factors, but primarily the lack of good alternatives. Fluoroquinolones, 
co-trimoxazole, and fosfomycin—as conventional agents for pros-
tatitis—were precluded by resistance. Imipenem and meropenem 
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Table 1. Antibiotic Susceptibilities for E. coli From Urine Culture
Antibiotic Interpretation,a MIC in mg/L
Amoxicillin-clavulanate R
Piperacillin-tazobactam R
Ceftriaxone R
Cefepime SDD (4 mg/L)
Ertapenem I (0.75 mg/L)
Imipenem S (0.5 mg/L)
Meropenem S (0.75 mg/L)
Ceftolozane-tazobactam R (>256 mg/L)
Ceftazidime-avibactam R (>256 mg/L)
Aztreonam S (1.5 mg/L)
Ciprofloxacin R
Gentamicin R
Tobramycin R
Trimethoprim-sulfamethoxazole R
Minocycline R (16 mg/L)
Doxycycline R (>256 mg/L)
Tigecycline S (0.380 mg/L)b
Fosfomycin R
Colistin S (0.250 mg/L)b
Abbreviations: I, intermediate; MIC, minimum inhibitory concentration; R, resistant; S, sus-
ceptible; SDD, susceptible dose-dependent.
aAccording to Clinical and Laboratory Standards Institute criteria (M100-S28, 2018).
bAccording to European Committee on Antimicrobial Susceptibility Testing criteria (v8.1, 
2018)
cAntimicrobial susceptibility of the clinical isolate was determined using disc diffusion, and 
the results were interpreted according to the breakpoints recommended by the Clinical 
and Laboratory Standards Institute. Minimum inhibitory concentrations were obtained 
using Etest (bioMérieux, France) and MTS (Liofilchem, Italy).
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were avoided, despite low minimum inhibitory concentrations 
(MICs), owing to presence of the blaNDM gene. Similar consider-
ations applied for aztreonam (MIC 1.5 mg/L), which is a substrate 
for CMY-2 and a likely substrate for TEM 164H enzyme that is 
expected to have ESBL activity [2]. Furthermore, penetration of 
β-lactams into prostatic tissue is poor, suggesting against their 
use (and that of aztreonam/avibactam, which would evade all the 
β-lactamases present). We avoided colistin because of the patient’s 
renal impairment, enhancing the risk of nephrotoxicity, [3] and 
because of this drug’s uncertain prostatic tissue penetration [4]. 
Eravacycline, a novel tetracycline, has lower MICs than tigecycline 
for Enterobacteriaceae [5] and might have been an alternative; how-
ever, data on prostatic penetration are lacking, and this antibiotic is 
not yet available in Switzerland.
Prostatitis presents a different challenge to urinary tract infec-
tions (UTIs), where any renally excreted antibiotic is potentially 
therapeutic. Penetration of antibiotics to the prostate occurs by 
passive diffusion from plasma and depends upon lipid solubility, 
dissociation constant, and protein binding [6]. Tetracyclines gen-
erally have good prostatic tissue and fluid penetration, but they 
are not appropriate for UTIs [6]. Although there are few data 
for tigecycline, minocycline, to which it is structurally related, 
achieves a prostatic tissue/serum ratio of 0.94 ± 0.39 [7]. Such con-
siderations, coupled with a steady-state serum level of c. 0.6 mg/L, 
suggest that adequate area under the curve/MIC ratios (the crit-
ical pharmacodynamic parameter for tigecycline [8]) should be 
achievable, as related to the susceptibility breakpoint (0.5 mg/L) of 
the European Committee on Antimicrobial Susceptibility Testing 
[9]. Tigecycline binds to ribosomal 30S subunits with greater af-
finity than earlier tetracyclines and evades the resistance conferred 
by acquired efflux and ribosomal protection [8].
To our knowledge, only 3 previous cases of prostatitis treated 
with tigecycline monotherapy have been reported [1, 10, 11]. 
All involved ESBL-producing E.  coli, and, despite significant 
differences in treatment duration (2, 6, and 22 weeks, respec-
tively), all showed favorable outcomes. Here we achieved mi-
crobiological eradication with tigecycline (MIC 0.38  mg/L). 
Residual nocturia and polyuria after treatment were interpreted 
in the context of known bladder neck sclerosis.
Tigecycline has a black box warning from the US Food and 
Drug Administration and is unsuitable for UTIs owing to 
largely biliary excretion. It has a mixed history as monotherapy 
in clinical trials, achieving noninferiority to comparators in 
skin and soft tissue infection (SSTI) [12], complicated Intra-
abdominal Infection (cIAI) [13], and community-acquired 
bacterial pneumonia (CABP) [14], but failing to do so in di-
abetic foot infection [15] and in the VAP arm of a ventilator-
associated penumonia/Hospital-aquired bacterial penumonia 
(VAP/HABP) trial [16]. It is most often used as a combination 
agent against MDR pathogens. Although larger trials or case 
series studies are needed, the present results support the view 
that prostatitis might be added to the list of infections where 
use as monotherapy can reasonably be considered, particularly 
against MDR E. coli.
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